Loading...

Rocket Pharmaceuticals

DB:9IP1
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
9IP1
DB
$838M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
9IP1 Share Price and Events
7 Day Returns
-8.9%
DB:9IP1
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
6%
DB:9IP1
-10.2%
DE Biotechs
-6%
DE Market
9IP1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Rocket Pharmaceuticals (9IP1) -8.9% -12% 5% 6% - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 9IP1 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 9IP1 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

9IP1 Value

 Is Rocket Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Rocket Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Rocket Pharmaceuticals.

DB:9IP1 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:9IP1
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (4.94%))
1.338
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.338 * 5.96%)
8.2%

Discounted Cash Flow Calculation for DB:9IP1 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Rocket Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:9IP1 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.2%)
2019 -67.00 Analyst x1 -61.92
2020 -118.00 Analyst x2 -100.79
2021 -99.00 Analyst x2 -78.15
2022 3.50 Analyst x2 2.55
2023 94.00 Analyst x2 63.38
2024 111.20 Est @ 18.29% 69.29
2025 125.51 Est @ 12.87% 72.29
2026 136.91 Est @ 9.08% 72.87
2027 145.71 Est @ 6.42% 71.68
2028 152.36 Est @ 4.57% 69.27
Present value of next 10 years cash flows $180.47
DB:9IP1 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $152.36 × (1 + 0.23%) ÷ (8.2% – 0.23%)
$1,915.19
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,915.19 ÷ (1 + 8.2%)10
$870.72
DB:9IP1 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $180.47 + $870.72
$1,051.19
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,051.19 / 49.61
$21.19
DB:9IP1 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:9IP1 represents 0.85586x of NasdaqGM:RCKT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85586x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 21.19 x 0.85586
€18.13
Value per share (EUR) From above. €18.13
Current discount Discount to share price of €14.46
= -1 x (€14.46 - €18.13) / €18.13
20.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Rocket Pharmaceuticals is available for.
Intrinsic value
20%
Share price is €14.46 vs Future cash flow value of €18.13
Current Discount Checks
For Rocket Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Rocket Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Rocket Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Rocket Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Rocket Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:9IP1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.89
NasdaqGM:RCKT Share Price ** NasdaqGM (2019-04-18) in USD $16.9
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Rocket Pharmaceuticals.

DB:9IP1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RCKT Share Price ÷ EPS (both in USD)

= 16.9 ÷ -1.89

-8.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rocket Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Rocket Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Rocket Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:9IP1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
4.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Rocket Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Rocket Pharmaceuticals's assets?
Raw Data
DB:9IP1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.30
NasdaqGM:RCKT Share Price * NasdaqGM (2019-04-18) in USD $16.9
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:9IP1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RCKT Share Price ÷ Book Value per Share (both in USD)

= 16.9 ÷ 4.30

3.93x

* Primary Listing of Rocket Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Rocket Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Rocket Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Rocket Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

9IP1 Future Performance

 How is Rocket Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Rocket Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Rocket Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Rocket Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Rocket Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:9IP1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:9IP1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 4.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:9IP1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:9IP1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 193 20 -50 3
2022-12-31 64 -21 -74 3
2021-12-31 1 -58 -137 3
2020-12-31 0 -103 -125 4
2019-12-31 0 -66 -116 5
DB:9IP1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -54 -75
2018-09-30 -39 -54
2018-06-30 -31 -44
2018-03-31 -24 -32
2017-12-31 -16 -20
2017-09-30 -12 -16
2017-06-30 -9 -11
2017-03-31 -8 -9
2016-12-31 -6 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Rocket Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Rocket Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:9IP1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Rocket Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9IP1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.76 -0.76 -0.76 1.00
2022-12-31 -1.13 -0.03 -2.22 2.00
2021-12-31 -2.25 -2.25 -2.25 1.00
2020-12-31 -2.39 -2.22 -2.53 4.00
2019-12-31 -2.63 -1.98 -3.12 5.00
DB:9IP1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.89
2018-09-30 -2.25
2018-06-30 -2.84
2018-03-31 -4.34
2017-12-31 -2.88
2017-09-30 -3.10
2017-06-30 -3.19
2017-03-31 -5.02
2016-12-31 -1.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Rocket Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Rocket Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Rocket Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

9IP1 Past Performance

  How has Rocket Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Rocket Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Rocket Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Rocket Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Rocket Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Rocket Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Rocket Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:9IP1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -74.52 12.59 53.08
2018-09-30 -53.85 11.46 34.32
2018-06-30 -44.49 11.02 26.15
2018-03-31 -32.24 7.63 18.19
2017-12-31 -19.58 4.86 14.73
2017-09-30 -15.85 3.73 12.13
2017-06-30 -10.99 2.37 8.61
2017-03-31 -8.86 1.92 6.94
2016-12-31 -7.57 1.58 5.99
2015-12-31 -8.41 0.37 6.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Rocket Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Rocket Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Rocket Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Rocket Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Rocket Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

9IP1 Health

 How is Rocket Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Rocket Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Rocket Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Rocket Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Rocket Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Rocket Pharmaceuticals Company Filings, last reported 3 months ago.

DB:9IP1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 194.04 41.45 205.73
2018-09-30 143.62 40.63 127.48
2018-06-30 157.08 39.84 132.10
2018-03-31 170.15 39.08 182.70
2017-12-31 15.52 0.00 18.14
2017-09-30 21.82 0.00 24.16
2017-06-30 27.88 0.00 28.30
2017-03-31 8.37 0.00 9.46
2016-12-31 8.37 0.00 9.46
2015-12-31 15.54 0.01 15.49
  • Rocket Pharmaceuticals's level of debt (21.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Rocket Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Rocket Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Rocket Pharmaceuticals has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 82.3% each year.
X
Financial health checks
We assess Rocket Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Rocket Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

9IP1 Dividends

 What is Rocket Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Rocket Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Rocket Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Rocket Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Rocket Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:9IP1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:9IP1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Rocket Pharmaceuticals has not reported any payouts.
  • Unable to verify if Rocket Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Rocket Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Rocket Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Rocket Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Rocket Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Rocket Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Rocket Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

9IP1 Management

 What is the CEO of Rocket Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Gaurav Shah
AGE 43
TENURE AS CEO 1.3 years
CEO Bio

Mr. Gaurav Shah, M.D. serves as the Chief Executive Officer, President and Director of Rocket Pharmaceuticals, Ltd since January 2018.

CEO Compensation
  • Insufficient data for Gaurav to compare compensation growth.
  • Insufficient data for Gaurav to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Rocket Pharmaceuticals management team in years:

1.3
Average Tenure
44
Average Age
  • The average tenure for the Rocket Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Gaurav Shah

TITLE
CEO, President & Director
AGE
43
TENURE
1.3 yrs

John Militello

TITLE
Controller
AGE
45
TENURE
1.3 yrs

Kinnari Patel

TITLE
Chief Operating Officer & Head of Development
AGE
39
TENURE
1.3 yrs

Claudine Prowse

TITLE
Senior Vice President of Corporate Strategy & IRO

Jonathan Schwartz

TITLE
Chief Medical Officer
AGE
54
TENURE
1.3 yrs

Raj Prabhakar

TITLE
Senior Vice President of Business Development & Operations
Board of Directors Tenure

Average tenure and age of the Rocket Pharmaceuticals board of directors in years:

1.3
Average Tenure
44
Average Age
  • The average tenure for the Rocket Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rod Wong

TITLE
Chairman
AGE
41
TENURE
1.3 yrs

Gaurav Shah

TITLE
CEO, President & Director
AGE
43
TENURE
1.3 yrs

Naveen Yalamanchi

TITLE
Independent Director
AGE
41
TENURE
1.3 yrs

Carsten Boess

TITLE
Director
AGE
51
TENURE
3.3 yrs

Pedro Granadillo

TITLE
Director
AGE
70
TENURE
1.3 yrs

Gotham Makker

TITLE
Independent Director
AGE
44
TENURE
1.3 yrs

David Southwell

TITLE
Director
AGE
57
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Apr 19 Buy RTW Investments, LLC Company 16. Apr 19 16. Apr 19 550,005 €15.50 €8,524,940
28. Dec 18 Buy RTW Investments, LLC Company 28. Dec 18 28. Dec 18 100,000 €12.17 €1,216,925
15. Dec 18 Sell David Southwell Individual 13. Dec 18 13. Dec 18 -38,768 €13.38 €-518,632
10. Dec 18 Buy Kinnari Patel Individual 06. Dec 18 06. Dec 18 5,675 €13.17 €74,759
29. Nov 18 Buy RTW Investments, LLC Company 27. Nov 18 27. Nov 18 967,742 €13.73 €13,282,501
X
Management checks
We assess Rocket Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Rocket Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

9IP1 News

Simply Wall St News

9IP1 Company Info

Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Details
Name: Rocket Pharmaceuticals, Inc.
9IP1
Exchange: DB
Founded:
$745,579,959
49,614,437
Website: http://www.rocketpharma.com
Address: Rocket Pharmaceuticals, Inc.
The Empire State Building,
Suite 7530,
New York,
New York, 10118,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RCKT Common Stock Nasdaq Global Market US USD 05. Jan 2018
DB 9IP1 Common Stock Deutsche Boerse AG DE EUR 05. Jan 2018
Number of employees
Current staff
Staff numbers
33
Rocket Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:05
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.